These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

192 related articles for article (PubMed ID: 38812778)

  • 1. Desensitizing the autonomic nervous system to mitigate anti-GD2 monoclonal antibody side effects.
    Mora J; Climent A; Roldán M; Flores MC; Varo A; Perez-Jaume S; Jou C; Celma MS; Lazaro JJ; Cheung I; Castañeda A; Gorostegui M; Rodriguez E; Chamorro S; Muñoz JP; Cheung NK
    Front Oncol; 2024; 14():1380917. PubMed ID: 38812778
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Novel infusion strategy reduces severe adverse events caused by the anti-GD2 monoclonal antibody naxitamab.
    Varo A; Castañeda A; Chamorro S; Muñoz JP; Gorostegui M; Celma MS; Lopez S; Simao M; Perez-Jaume S; Mora J
    Front Oncol; 2023; 13():1164949. PubMed ID: 37213300
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Immunotherapy with anti-G
    Kushner BH; Modak S; Kramer K; Basu EM; Iglesias-Cardenas F; Roberts SS; Cheung NV
    Int J Cancer; 2023 Jan; 152(2):259-266. PubMed ID: 35913764
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Chimeric antibody c.8B6 to O-acetyl-GD2 mediates the same efficient anti-neuroblastoma effects as therapeutic ch14.18 antibody to GD2 without antibody induced allodynia.
    Terme M; Dorvillius M; Cochonneau D; Chaumette T; Xiao W; Diccianni MB; Barbet J; Yu AL; Paris F; Sorkin LS; Birklé S
    PLoS One; 2014; 9(2):e87210. PubMed ID: 24520328
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Multidisciplinary Clinical Care in the Management of Patients Receiving Anti-GD2 Immunotherapy for High-Risk Neuroblastoma.
    Cabral J; Fernandez EI; Toy B; Secola R
    Paediatr Drugs; 2023 Jan; 25(1):13-25. PubMed ID: 36434427
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A monoclonal antibody to O-acetyl-GD2 ganglioside and not to GD2 shows potent anti-tumor activity without peripheral nervous system cross-reactivity.
    Alvarez-Rueda N; Desselle A; Cochonneau D; Chaumette T; Clemenceau B; Leprieur S; Bougras G; Supiot S; Mussini JM; Barbet J; Saba J; Paris F; Aubry J; Birklé S
    PLoS One; 2011; 6(9):e25220. PubMed ID: 21966461
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Naxitamab: a humanized anti-glycolipid disialoganglioside (anti-GD2) monoclonal antibody for treatment of neuroblastoma.
    Slatnick LR; Jimeno A; Gore L; Macy ME
    Drugs Today (Barc); 2021 Nov; 57(11):677-688. PubMed ID: 34821881
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The GD2-specific 14G2a monoclonal antibody induces apoptosis and enhances cytotoxicity of chemotherapeutic drugs in IMR-32 human neuroblastoma cells.
    Kowalczyk A; Gil M; Horwacik I; Odrowaz Z; Kozbor D; Rokita H
    Cancer Lett; 2009 Aug; 281(2):171-82. PubMed ID: 19339105
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinical and Pathological Evidence of Anti-GD2 Immunotherapy Induced Differentiation in Relapsed/Refractory High-Risk Neuroblastoma.
    Mora J; Castañeda A; Colombo MC; Gorostegui M; Gomez F; Mañe S; Santa-Maria V; Garraus M; Macias N; Perez-Jaume S; Muñoz O; Muñoz JP; Barber I; Suñol M
    Cancers (Basel); 2021 Mar; 13(6):. PubMed ID: 33809255
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Toxicity Spectrum of Anti-GD2 Immunotherapy: A Real-World Study Leveraging the US Food and Drug Administration Adverse Event Reporting System.
    Wang G; Wang J; Du R; Wang Y; Li Z
    Paediatr Drugs; 2024 Mar; 26(2):175-185. PubMed ID: 38153627
    [TBL] [Abstract][Full Text] [Related]  

  • 11. GM-CSF, G-CSF or no cytokine therapy with anti-GD2 immunotherapy for high-risk neuroblastoma.
    Mora J; Modak S; Kinsey J; Ragsdale CE; Lazarus HM
    Int J Cancer; 2024 Apr; 154(8):1340-1364. PubMed ID: 38108214
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Naxitamab Activity in Neuroblastoma Cells Is Enhanced by Nanofenretinide and Nanospermidine.
    Galassi L; Rossi M; Lodeserto P; Lenzi M; Borsetti F; Voltattorni M; Farruggia G; Blasi P; Orienti I
    Pharmaceutics; 2023 Feb; 15(2):. PubMed ID: 36839972
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Survival Impact of Anti-GD2 Antibody Response in a Phase II Ganglioside Vaccine Trial Among Patients With High-Risk Neuroblastoma With Prior Disease Progression.
    Cheung IY; Cheung NV; Modak S; Mauguen A; Feng Y; Basu E; Roberts SS; Ragupathi G; Kushner BH
    J Clin Oncol; 2021 Jan; 39(3):215-226. PubMed ID: 33326254
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prolonged progression-free survival after consolidating second or later remissions of neuroblastoma with Anti-G
    Kushner BH; Ostrovnaya I; Cheung IY; Kuk D; Kramer K; Modak S; Yataghene K; Cheung NK
    Oncoimmunology; 2015 Jul; 4(7):e1016704. PubMed ID: 26140243
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Anti-GD2 immunotherapy for neuroblastoma.
    Sait S; Modak S
    Expert Rev Anticancer Ther; 2017 Oct; 17(10):889-904. PubMed ID: 28780888
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pain mitigation and management strategies for anti-GD2 infusions: An expert consensus.
    Nysom K; Morad AG; Rafael MS; Zier J; Marachelian A; Watt T; Morgenstern DA
    Pediatr Blood Cancer; 2023 May; 70(5):e30217. PubMed ID: 36772891
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Targeting GD2-positive Refractory/Resistant Neuroblastoma and Osteosarcoma with Anti- CD3 x Anti-GD2 Bispecific Antibody Armed T cells.
    Yankelevich M; Thakur A; Modak S; Chu R; Taub J; Martin A; Schalk DL; Schienshang A; Whitaker S; Rea K; Lee DW; Liu Q; Shields A; Cheung NK; Lum LG
    Res Sq; 2023 Nov; ():. PubMed ID: 37986911
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Spotlight on dinutuximab in the treatment of high-risk neuroblastoma: development and place in therapy.
    Keyel ME; Reynolds CP
    Biologics; 2019; 13():1-12. PubMed ID: 30613134
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Anti-GD2 Directed Immunotherapy for High-Risk and Metastatic Neuroblastoma.
    Chan GC; Chan CM
    Biomolecules; 2022 Feb; 12(3):. PubMed ID: 35327550
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Transition to a mesenchymal state in neuroblastoma may be characterized by a high expression of GD2 and by the acquisition of immune escape from NK cells.
    Di Matteo S; Bilotta MT; Pelosi A; Haas D; Theinert T; Weber G; Schlegel PG; Berg M; Moretta L; Maggi E; Azzarone B; Vacca P; Tumino N; Caruana I
    Front Immunol; 2024; 15():1382931. PubMed ID: 38736882
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.